RELA Recombinant Protein (OPCD06661)

Catalog No: OPCD06661

RELA Recombinant Protein (OPCD06661) using SDS-PAGE

RELA Recombinant Protein (OPCD06661) using SDS-PAGE

Product Info

• Predicted Species Reactivity: Homo sapiens|Human
• Product Format: Freeze-dried Powder. PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
• Host: E.coli
• Conjugation: Unconjugated
• Application: Positive control|Sodium sodecyl sulfate - polyacrylamide gel electrophoresis|Western blot
• Additional Information: Endotoxin Level: < 1.0 EU per 1 ug (determined by the LAL method)
  Tisue Specificity: Nucleus, Cytoplasm, Chromosome
  Isoelectric Point: 8.8
  Residues: Pro19-Tyr306
• Reconstitution and Storage: 2°C to 8°C|-80°C
• Concentration: 200 ug/mL (prior to lyoph)
• Purity: > 90%
• Source: E.coli
• Tag: N-terminal His Tag

Target Info

• Gene Symbol: RELA
• Gene Full Name: RELA proto-oncogene, NF-kB subunit
• Alias Symbols: CMCU;NF-kappa-B p65delta3;NF-kappa-B transcription factor p65;NFKB3;nuclear factor NF-kappa-B p65 subunit;nuclear factor of kappa light polypeptide gene enhancer in B-cells 3;p65;transcription factor p65;v-rel avian reticuloendotheliosis viral oncogene homolog A.
• NCBI Gene Id: 5970
• Protein Name: Transcription factor p65
• Description of Target: NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681).
• Uniprot ID: Q04206
• Protein Accession #: NP_001138610.1
• Nucleotide Accession #: NM_001145138.1
• Protein Size (# AA): Pro19~Tyr306
• Molecular Weight: 37kDa